Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma
Active, not recruiting · Phase 1 · NCT02159755
Conditions: Recurrent Mantle Cell Lymphoma
At a glance
- Research payments reported, 2025
- $927,268
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 28
About the trial
- Sponsor
- National Cancer Institute (NCI)
- Tested
- Ibrutinib (drug), Laboratory Biomarker Analysis (other), Palbociclib (drug), Pharmacological Study (other)
- Dates
- Started 2014-08-13; completion 2027-04-30
- Results posted
- Not yet
This phase I trial studies the side effects and best dose of ibrutinib and palbociclib in treating patients with previously treated mantle cell lymphoma. Ibrutinib and palbociclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Palbociclib may also help ibrutinib work better by making cancer cells more sensitive to the drug.
From ClinicalTrials.gov, last updated 2026-05-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $927,268 in research payments for this study in 2025 (9 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- National Institute of Health $927,268
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.